Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Jan 9;47(1):4.
doi: 10.1186/s40463-017-0247-6.

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis

Woon Won Kim  1 , Tae Kwun Ha  2 , Sung Kwon Bae  3
Affiliations
Comparative Study

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis

Woon Won Kim et al. J Otolaryngol Head Neck Surg. .

Abstract

Background: The purpose of this study was to examine the possible prognostics and clinicopathologic characteristics underlying the BRAFV600E mutation and papillary thyroid carcinoma (PTC) coexisting or in absence of chronic lymphocytic thyroiditis (CLT).

Methods: This study was conducted on 172 patients who had undergone total thyroidectomy or unilateral total thyroidectomy for PTC; the patients were then examined for the BRAFV600E mutation using specimens obtained after their surgery from January 2013 to August 2015.

Results: BRAF mutations were found in 130 of 172 patients (75.6%). CLT was present in 27.9% of patients (48/172). The incidence of the BRAFV600E mutation was significantly increased in the group with no CLT (P = 0.001). The findings of the multivariate analysis pertaining to the coexistence of CLT and PTC showed no significant correlation other than the BRAFV600E mutation. No significant difference was noted in the clinicopathologic factors between the two groups based on the coexistence of CLT in univariate and multivariate analyses.

Conclusions: The BRAFV600E mutation is less frequent in PTC coexisting with CLT presumably because CLT and the BRAFV600E mutation operate independently in the formation and progression of thyroid cancer.

Keywords: BRAF mutation; Chronic lymphocytic thyroiditis; Papillary thyroid carcinoma.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by Inje University Busan Paik Hospital institutional review board

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Paschke R, Lincke T, Müller SP, Kreissl MC, Dralle H, Fassnacht M. The Treatment of Well-Differentiated Thyroid Carcinoma. Dtsch Arztebl Int. 2015;112(26):452–458. - PMC - PubMed
    1. Ito Y, Miyauchi A, Kobayashi K, Kihara M, Miya A. Static and dynamic prognostic factors of papillary thyroid carcinoma. Endocrine journal. 2014;61(12):1145–1151. doi: 10.1507/endocrj.EJ14-0303. - DOI - PubMed
    1. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058–1069. doi: 10.1016/S0140-6736(13)60109-9. - DOI - PMC - PubMed
    1. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, et al. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene. 2011;30:3153–3162. doi: 10.1038/onc.2011.44. - DOI - PMC - PubMed
    1. Zhang Y, Ma X-p, Deng F-s, Liu Z-r, Wei H-q, Wang X-h, Chen H. The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer. World J Surg Oncol. 2014;12:277. doi: 10.1186/1477-7819-12-277. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances